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a  b  s  t  r  a  c  t
A  World  Health  Organization  (WHO)  consultation  on  guidelines  for National  Regulatory  Authorities
(NRAs)  and  vaccine  manufacturers  on clinical  evaluation  of  vaccines  was  held  from  17  to 18  July  2014,
to  review  key  scientiﬁc  challenges  that  regulators  have  been  facing  since  the establishment  of  the WHO
Guidelines  on  Clinical  Evaluation  of Vaccines.  The  guidelines,  adopted  by the  WHO  Expert  Committee
on  Biological  Standardization  (ECBS)  in  2001,  have  served  as the  basis  for  setting  or updating  national
requirements  for the  evaluation  and  licensing  of  a broad  range  of vaccines  as  well  as  for  WHO  vaccine
prequaliﬁcation.  Regulators  from  Australia,  Brazil,  China,  Canada,  Germany,  India,  Republic  of  Korea,
South  Africa,  United  States  of America  and  the  United  Kingdom  were  represented.  The  International
Federation  for Pharmaceutical  Manufacturers’  Association  (IFPMA)  and  the  Developing  Country  Vaccine
Manufacturers’  Network  (DCVMN)  provided  industry  representation.
The consultation  concluded  that  the  guidelines  should  be revised  to address  issues  that were  raised  in
the context  of  vaccines  that  were  the  subject  of  clinical  development  in  the  past  decade.  Although  the
current  guidelines  have  served  well  over  time,  it was  recognized  that  an  update  would  further  increase
their  utility  and would  help  regulators,  manufacturers,  vaccine  developers  and  academia  to  respond  to
the challenging  questions  regarding  the  safety,  immunogenicity,  efﬁcacy  and  effectiveness  of  vaccines
intended  for  global  use.  A summary  of  the main  outcomes  of  the  consultation  and  proposals  for the  next
steps  regarding  the  guidelines  and beyond  are  provided  in  this  report.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Background information
The WHO  Guidelines on Clinical Evaluation of Vaccines were
dopted by the WHO  Expert Committee on Biological Standard-
zation (ECBS) in 2001 and published in the WHO  Technical Report
eries (TRS) 924, Annex 1. The guidelines provide a number of guid-
ng principles for regulatory review of clinical data and it has served
s a basis for setting or updating national requirements for the eval-
ation and licensing of a broad range of vaccines as well as for WHO
accine prequaliﬁcation.
Among other messages that the WHO  Guidelines have conveyed
ince their establishment, is the role of National Regulatory Author-
ties (NRAs), the importance of clearly deﬁning national require-
ents and early dialogue between vaccine manufacturers and
egulators were emphasized as key elements of effective regulation.
∗ Corresponding author. Tel.: +41 227913136.
E-mail address: knezevici@who.int (I. Knezevic).
ttp://dx.doi.org/10.1016/j.vaccine.2015.01.056
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2. Aim of the WHO  consultation in July 2014
A WHO  consultation on guidelines for NRAs and vaccine man-
ufacturers on clinical evaluation of vaccines was  held from 17 to
18 July 2014, to review key scientiﬁc challenges that regulators
have been facing since the establishment of the WHO  Guidelines
on Clinical Evaluation of Vaccines. The consultation aimed to iden-
tify a need for updating the guidelines and to also reach a consensus
on the key issues that need to be addressed in the revision. This is
the ﬁrst step in initiating a broader consultation on this topic with
experts from WHO  Member States.
The consultation was organized by the WHO  Technology, Norms
and Standards team of the Department of Essential Medicines
and Health (EMP/RHT/TSN) and the Initiative for Vaccine Research
(IVR/IVB) team. Dr James Southern chaired the consultation and Dr
Rebecca Sheets served as the Rapporteur.Regulators, manufacturers, clinical researchers and academic
investigators from Australia, Brazil, China, Canada, Germany, India,
Republic of Korea, South Africa, United States of America and the
United Kingdom were represented. The International Federation for
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harmaceutical Manufacturers’ Association (IFPMA) and the Devel-
ping Country Vaccine Manufacturers’ Network (DCVMN) provided
ndustry representation.
. Challenging issues in clinical evaluation of vaccines from
 perspective of regulators and manufacturers
As part of the preparation for the consultation, participants were
nvited by WHO  to review the guidelines on clinical evaluation
f vaccines and to prepare some comments and proposals for its
evision.
Regulators from several countries presented their answers to
he following three questions regarding the situation in their own
ountry:
Which WHO  or other international guidelines are actually used?
What is implemented into local guidelines/regulations?
What are additional topics needed in the revision of this WHO
guideline?
.1. Regulators (Australia, Brazil, China, India, Republic of Korea,
outh Africa)
Presentations were provided by the NRA representatives from
he countries listed above, although other NRAs were present and
rovided comments and discussion. In general, a number of WHO
uidelines, including the Guidelines on Clinical Evaluation of Vac-
ines are used by NRAs—either adopted or adapted as their own
ocal guidelines or incorporated by reference or indirectly incorpo-
ated into their regulations or laws. For example, Brazil endorses
he PANDRH document on Licensing of Vaccines in the Americas,
hich refers to the WHO  Guidelines on Clinical Evaluation of Vac-
ines.
Other common themes raised by the NRAs were to provide clar-
ty regarding the use of the Brighton Collaboration diagnostic and
ase deﬁnitions vs. the use of mEDRA coding in reporting of adverse
vents (AEs); clarity on the requirement for and timing of clinical
tudies to support lot-to-lot consistency; clarity on which aspects
f the WHO  guidelines pertained primarily to novel or new vaccines
containing components that have not been used in previously
icensed or registered vaccines) and those applicable to follow-on
accines; vaccines that have been tech-transferred to a new in-
ountry manufacturer; or vaccines formulated from components
bulks) already included in existing licensed or registered vaccines.
he latter categories of vaccines would not generally need the same
xtensive clinical trial programme that completely novel or new
accines would require. However, the current guidelines are silent
n that regard and may  be misinterpreted to suggest that all types
f vaccines, no matter the degree of pre-existing data on the same
r similar immunogens contained in existing vaccines, would need
he same clinical development programme, which is not the case.
The consultation recognized that the revision of the guidelines
s an important step in assisting WHO  Member States in devel-
ping or updating national requirements for clinical evaluation of
accines. However, these guidelines are not expected to resolve all
ractical issues and therefore, it was also considered what should
e provided as additional tools in assisting regulators on that mat-
er. As an example, WHO  activities in facilitating implementation of
uiding principles into regulatory and manufacturing practice were
ecognized as an essential tool towards better regulatory prepared-
ess and convergence. Furthermore, requests were made for some
raining materials that need to be developed or updated in order
o provide tools for building expertise for clinical evaluation in
eveloping countries. A need for scientiﬁc advice as a complemen-
ary tool to facilitate application of guiding principles in speciﬁc3 (2015) 1999–2003
cases was identiﬁed. The utility of regional expertise and collabo-
ration within such groups as the African Vaccine Regulatory Forum
(AVAREF) and the Developing Country Vaccine Regulators’ Network
(DCVRN) was duly recognized.
3.2. Vaccine developers and manufacturers (IFPMA & DCVMN)
Representatives from IFPMA and DCVMN provided their input
on the issues that need to be updated or amended in the exist-
ing guidelines. Their feedback was  in-line with comments and
discussion of other presenters and they provided some practi-
cal and valuable feedback on the impact, sometimes unintended
by the original authors, of some of the language or lack of clar-
ity in the guidelines—which can be amended in the revision to
improve understanding by all parties. It was  agreed that their sug-
gestions would improve the guidelines for all users. The importance
of applying principles on a case-by-case basis was  discussed. For
instance, it is stated in the guidelines that Phase I is “primarily”
intended for safety evaluation but it does not mean that immuno-
genicity should not be done in that study, when appropriate. A need
for ﬂexible approach in a given situation is essential for science
based regulation.
4. Revision of WHO  Guidelines on Clinical Evaluation of
Vaccines
It was agreed that the guidelines should be revised and updated.
Below is a summary of the main outcomes of the discussion and
speciﬁc agreements regarding purpose, scope, etc.
4.1. Main outcomes of discussion
Many issues were discussed and the outcomes are described
below thematically. One issue not covered in the current guidelines,
but important, is that of conducting human challenge studies and
their potential role in vaccine development. Also, there are some
safety considerations related to challenge trials that need to be
considered in the revision. The experience gained with more than
ten pathogens clearly show that these studies provide important
information about the disease as well as for vaccines under devel-
opment, notably P. falciparum malaria, typhoid and cholera. Some
of the lessons learned, in particular, in low- and middle-income
countries, may  serve as a starting point for deﬁning regulatory con-
siderations for these studies. But there are many other issues that
would be more appropriate for vaccine developers and therefore,
would most likely require a separate document.
In addition, it was  agreed to address some special consider-
ations for combined vaccines apart from DT-based combinations.
The need for separate guidance on special considerations for adju-
vanted vaccines was  recognized, as there are WHO  Guidelines on
Nonclinical Evaluation of Adjuvants and Adjuvanted Vaccines, but
no speciﬁc clinical guidelines on the same.
One of the topics of importance for global immunization practice
which goes beyond regulatory issues is that of maternal immuniza-
tion. Pregnant women may  be vaccinated for different purposes;
either to protect themselves where pregnancy is a speciﬁc risk
group for a particular disease, or to protect their neonate, once
born, for example, tetanus, inﬂuenza and pertussis. Given that
pregnant women  are increasingly recognized as one of the priority
target groups for immunization in some vaccine areas, the issue
of maternal immunization was  proposed as an appendix to the
revised guidelines. The intention is to provide some guiding princi-
ples for studies carried out on pregnant women  and women  during
the lactation period on the one hand and to elaborate on mater-
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xample, tetanus, pertussis, inﬂuenza, RSV, Group B Streptococcus
nd CMV.
Several aspects of early clinical trials were also discussed. While
xperimental medicines and translational research have expanded
n scope since the publication of the current guidelines, it was  felt
hat it may  still be premature to provide speciﬁc guidelines for clin-
cal trials performed for the purpose of experimental medicines
ather than speciﬁc product development. However, translational
esearch sometimes transitions to product development. There-
ore, it would be appropriate to discuss this issue in the context
f the recently appointed WHO  Product Development for Vaccines
dvisory Committee. Acknowledgement, however, that trials may
e performed for the purposes of experimental medicines and/or
ranslation research should be noted in these guidelines.
The experience gained with adaptive clinical trial designs was
iscussed in the context of regulatory considerations and it was
greed to provide a brief explanation on the characteristics of such
rials, as there may  be confusion. For instance, predeﬁned crite-
ia for expected changes to clinical trial conduct were described
s a ﬂexible approach which is intended to facilitate development
f novel vaccines in certain cases. One of the difﬁculties is that
he statistical analysis of the data from an adaptive trial design is
xceedingly complex and should take into account these prospec-
ively planned changes and their impact on the power of the study.
ince the use of adaptive trial design to support vaccine devel-
pment is still a concept under development from the regulatory
erspective, it would be sufﬁcient to provide brief information, cite
urrent literature that elaborates in much greater detail and maybe
rovide some examples on the appropriate uses of such studies.
It was noted that preliminary efﬁcacy studies, often called Phase
Ib studies, have been a major feature of several clinical develop-
ent programmes (for example, malaria, dengue, HIV, tuberculosis,
PV). It was agreed that the value of Phase IIb studies as well as the
ituations where such studies may  be needed should be described
n a reasonably concise way. It was also discussed that the nomen-
lature of Phases I, Ia and Ib, Phases II, IIa and IIb and Phase III can
ecome semantics and to describe the intent and purpose of the
rial as a primary deﬁning characteristic of where it ﬁts into the
verall clinical development programme should be clariﬁed in the
evision of the guidelines.
An additional key issue identiﬁed to be included in the revi-
ion of the guidelines was a need to provide greater clarity on the
sliding scale” or progressive nature of the rigour of expectations
or product quality; how nonclinical studies inform clinical trials
nd rigour of expectations for assays (both quality and clinical) as
linical trials progress in all Phases. Speciﬁcally, expectations that
t Phase I (particularly, ﬁrst-in-human studies) there will be lot-to-
ot consistency; process validation; stringent lot release criteria; all
onclinical studies completed and immunological or clinical end-
oint assays validated; is unrealistic and inappropriate. While such
xpectations are realistic at or during Phase III (or pivotal clinical
rials), they are not at Phase I. This is not to suggest that scientiﬁc
igour and good practices should not be implemented by Phase I,
ut rather that not all facets will be ready at such an early stage
f product development, since the purpose of product and clinical
evelopment is to reﬁne and improve all of these things so that by
he time of commercialization, an optimized, validated, consistent
roduct may  be launched.
Increasingly, vaccines are being developed that will likely have
 great impact on public health, but which will not achieve nearly
he degree of vaccine efﬁcacy (VE) seen with legacy vaccines like
olio or measles. New vaccines of modest efﬁcacy may  help to curb
isease burden where it is high, but these places may  be exactly
hose where the regulatory experience has mainly been gained with
accines of extremely high efﬁcacy. Thus, some discussion on eval-
ating the risk and beneﬁt of a vaccine based on the level of efﬁcacy3 (2015) 1999–2003 2001
shown, whatever that level may  be, is needed in the guidelines.
Understanding the power of the statistics and what they demon-
strate and the potential need for more than one concordant study
to gain conﬁdence that a modestly efﬁcacious vaccine can actually
be effective is important.
Another issue that garnered signiﬁcant discussion was  that of
the requirement for local, in-country data and the reluctance to
accept foreign data for the purposes of licensure (or even initia-
tion of advanced clinical trials) in any particular country. The need
to consider study designs that permit efﬁcient capture of data in
geographically disperse or genetically diverse populations to give
sufﬁcient power to permit countries to accept foreign data was
recognized and should be discussed in the revised guidelines. The
intent is that the perceived need to require local data should not
deter the introduction of efﬁcacious vaccines for populations of
greatest need at the earliest appropriate moment and where pos-
sible, to avoid conduct of small studies with no valid scientiﬁc
purpose.
Finally, there was consideration on better ways to describe the
statistics of sample sizes needed to acquire safety data. The cur-
rent guidelines have numbers such as “300” or “5000,” which while
they have a statistical basis—that basis is not described and is not
always appropriate, leading to potential inﬂexibility. Rather, dis-
cussion should be on the need to statistically calculate a sample size
that will permit collection of safety data that will permit identiﬁca-
tion of common (1/100) and uncommon (for example, 1/1000) AEs.
Also, there needs to be a recognition and acknowledgement that not
all safety issues may  be fully characterized at the time of licensure
and thus, to discuss when there is a need for post-approval collec-
tion of safety and in fact, effectiveness, data, among other issues
that can only be addressed once a vaccine is in more wide-spread
use.
4.2. Consensus statement on key issues to be addressed
4.2.1. Purpose of the guidelines
It was agreed that the purpose of the guidelines are to support
both clinical trial approval and licensure or registration of vaccines
and not just solely the latter. It was also agreed that the guide-
lines are meant to inform not only regulators, but also industry
and researchers about regulatory expectations, although the main
purpose of the guidelines are to aid regulators in their clinical eval-
uation of vaccines.
4.2.2. Scope
It was  agreed that the scope of the guidelines would be pro-
phylactic vaccines and would not tackle therapeutic vaccines for
which clinical development could be quite different. Also, many
aspects that are in the current guidelines are no longer appropriate
for the scope of this document given that there are newer WHO
guidelines that cover those speciﬁc topics, such as nonclinical eval-
uation and aspects of good clinical practices (GCP), in particular
ethical considerations. While ethical considerations that are rele-
vant to clinical evaluation or clinical trial design will necessarily
be discussed within appropriate sections of the revised guidelines
(for example, the use of a placebo control group or choice of con-
trol group(s)), a separate section on ethical considerations will no
longer appear, as this would have the potential to conﬂict with the
WHO guidelines on GCP and for ethics review committees and those
documents should supersede.4.2.3. Additional points
Additional points to those raised in the section on Main Out-
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the concept of heterologous prime-boost regimens;
what to do in the case of hyporesponsiveness to vaccination in
certain populations;
how to identify and deﬁne immune correlates of protection,
including threshold values and what to avoid in order to not
misuse these;
vaccines that may  have short durability of protection;
concern for biocreep or immunological “creep” when selecting a
choice of control group;
size of safety databases by sub-groups (for example, age);
situations in which age de-escalation studies may  be inappropri-
ate;
use of a comparator arm that may  not be licensed in the country
where the trial is being performed or which may  be of unknown
efﬁcacy;
use of live or replication-incompetent viral vectors as vaccines for
diseases other than that caused by the virus used as the vector;
clarifying roles of the sponsor vs. public health authorities in post-
approval data collection and analysis;
concomitant use of vaccines
evaluating the need for booster doses in the faces of waning
immunity; and
discerning whether waning immunity correlates with waning
efﬁcacy or not, among others.
.2.4. Updates
Sections that require updating were discussed and those aspects
here additional clarity or revision is needed will be addressed by
he drafting group. Some of these aspects are mentioned above in
he section on the Main Outcomes of the Discussion.  Also, it was
oted that the Glossary requires updating and deﬁnitions provided
or several keywords (for example, licensure, registration and lot
onsistency are among others).
.2.5. Other changes
It was agreed that the Table of Contents will be revised and that
ertain sections will be deleted and the information in those sec-
ions placed into other appropriate places or deleted altogether as
hey are covered by other, newer WHO  Guidelines—(for example,
he sections on General Remarks, Methodological Considerations,  Sta-
istical Considerations and Ethical Considerations). It was agreed that
hatever decision is taken concerning the Table of Contents, it will
lways be made clear how different principles and considerations
pply at different stages of development, and this must be made
lear in the drafting of the revised guidelines. It may  be appropriate
o include numbered subsections on early and late stage develop-
ental considerations for each content area, where appropriate.
. Conclusions and pathway forward
It was concluded that there were very few issues in the current
uidelines that were altogether out-of-date. Nonetheless, a num-
er of points were proposed to be included as additional issues to
e addressed and that the organization of the guidelines could be
mproved to reduce redundancy and improve ﬂow of information
n a more logical order. It was universally agreed that the existing
uidelines have been of great value to regulators and industry alike,
s well as researchers. The consultation concluded with agreement,
hat the guidelines should be revised to address issues that were
aised in the context of vaccines that were the subject of clinical
evelopment in the past decade. Although the current guidelines
ave served well over time, it was recognized that an update
ould further increase their utility and would help regulators,
anufacturers, vaccine developers and academia to understand3 (2015) 1999–2003
expectations in terms of safety, immunogenicity, efﬁcacy and effec-
tiveness data that are needed for vaccines intended for global use.
5.1. Plan for revision of the guidelines
A drafting group has been identiﬁed and will initiate writing of
the revision of the guidelines with plans to complete this by the end
of 2014 or in early 2015. The ﬁrst rough draft of the revision will
be circulated to participants who took part in the consultation and
other critical reviewers to improve it before circulating it for pub-
lic comment. Revisions will be made by the drafting group before
the guidelines are circulated for public comment. It is likely that
at least three rounds of circulation to critical reviewers and public
comment will be undertaken before a ﬁnal draft will be submitted
to the ECBS for review and adoption at the next meeting to be held
in October 2015.
5.2. Beyond the guidelines
The consultation did recognize that the guidelines can only go so
far in supporting capacity building of developing country regulators
and assuring that vaccines are licensed or registered and access
given to the populations of greatest need in as rapid a fashion as
prudent and appropriate. Some of the additional needs for these
goals were discussed brieﬂy:
5.2.1. Training materials and e-learning tools needed
The guidelines by their very nature, must be written generically
and ﬂexibly and not all aspects will apply in all circumstances and
situations. Training and experience is also needed to know when to
apply which aspects and speciﬁc examples and case studies can aid
in such training. Thus, to supplement what the guidelines cannot
do, development of training materials and e-learning tools were
requested by some NRAs present at the consultation. Access to sci-
entiﬁc expert advice in some manner to assist NRAs in their review
process was also requested.
5.2.2. Implementation of guidelines into practice
To be truly effective, the guidelines need to be implemented
into practice. To facilitate this, WHO  plans to hold one or more
implementation workshops once the ECBS has adopted the revised
guidelines. Further discussion on implementation may  occur at
later stages of development of the revision.
5.2.3. Vaccine Trial Registries
Vaccine Trial Registries as international databases provide valu-
able information on the latest clinical trials conducted for vaccines
of interest. Also recognized was the importance of ensuring repor-
ting of important clinical trial results in a reasonable timeframe and
some recent literature that suggests that as many as 30% of com-
pleted trials are not reported within two years or even up to six
years after completion (Manzoli et al., BMJ  2014;348:g3058). Pro-
viding a clear deﬁnition on when a trial is considered completed
might assist in this regard, as some sponsors will not consider a trial
completed even long after the last study visit and primary or even
secondary analyses, if there continues to be some type of longer-
term follow-up going on in the study (for example, yearly phone
calls for up to ﬁve years after the last study injection).
DisclaimerThis article contains the views of the authors and does not nec-
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